The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 8)

• AstraZeneca plc (ADR) AZN
• Bio-Rad Laboratories, Inc. BIO(reported forecasting-beating results for Q2)
• Endo International PLC ENDP(reacted to a beat-and-raise quarter)
• Inspire Medical Systems Inc INSP(reported a narrower-than-expected Q2 loss and forecast 50-54 percent revenue growth for FY18)
• Horizon Pharma PLC HZNP(reacted to quarterly results)
• Inogen Inc INGN(reported above-consensus EPS for Q2 and raised its FY18 guidance)
• Medtronic PLC MDT
• OptimizeRx Corporation OPRX(reacted to Q2 results)
• Pfizer Inc. PFE
• SurModics, Inc. SRDX

Zoetis Inc ZTS

Down In The Dumps

(Biotech Stocks Hitting 52-week lows on Aug. 8)

• Aileron Therapeutics Inc ALRN(reported a wider-than-expected Q2 loss)
• Cesca Therapeutics Inc KOOL
• Citius Pharmaceuticals Inc CTXR
• Clovis Oncology Inc CLVS
• CTI BioPharma Corp CTIC
• Cytori Therapeutics Inc CYTX
• Enzo Biochem, Inc. ENZ
• Flex Pharma Inc FLKS
• OHR Pharmaceutical Inc OHRP
• Pain Therapeutics, Inc. PTIE
• Provention Bio Inc PRVB
• Pulmatrix Inc PULM
• Reshape Lifesciences Inc RSLS
• Sonoma Pharmaceuticals Inc SNOA
• Synlogic Inc SYBX
• Titan Medical Inc. TMDI(announced pricing of offering)

Stocks In Focus

Ampio, Regenxbio Slip On News of Common Stock Offering

Ampio Pharmaceuticals Inc AMPE announced its intention to offer shares and accompanying warrants to purchase shares of common stock in an underwritten public offering. The stock plunged 26.08 percent to $0.45 in after-hours trading.

Regenxbio Inc RGNX said it intends to offer $175 million worth of its common stock in an underwritten public offering. The stock declined 3.68 percent to $68 in after-hours session.

Sangamo Blood Disorder Drug Trial Produces Positive Results

Sangamo Therapeutics Inc SGMO announced positive preliminary data from the Phase 1/2 trial that evaluates its SB-525, a cDNA gene therapy candidate for Hemophilia A. The candidate has been developed under a collaboration between Sangamo and Pfizer Inc. PFE.

"In the Alta study, SB-525 has been generally well tolerated to date with no treatment-related serious adverse events and no use of tapering courses of oral steroids," Sangamo said.

Separately, the company reported a wider-than-expected loss for its Q2.

The stock rose 3.57 percent to $14.345 in after-hours trading.

Related Link: Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Stocks Reacting To Earnings

Teligent Inc TLGT said Q2 revenues fell 9 percent year-over-year to $16.8 million. The loss per share also came in wider than expectations. The stock slumped 11.84 percent to $3.50 in after-hours trading.

Insys Therapeutics Inc INSY reported a decline in revenues from $42.6 million in Q2'17 to $23.5 million in Q2, dragged by lower gross revenue and returns of expired product. The loss per share widened from 11 cents to 37 cents. The stock fell 6.01 percent to $7.35 in after-hours trading.

Akebia Therapeutics Inc AKBA said its Q2 loss per share widened from 53 cents to 60 cents, while analysts estimated a narrower loss of 51 cents per share. Collaboration revenues rose from $28.52 million to $48.79 million. The stock plunged 12.55 percent to $8.50 in after-hours trading.

Rigel Pharmaceuticals, Inc RIGL reported a Q2 loss of 16 cents per share, flat with last year and also in line with estimates. The company reported revenues of $1.79 million. The stock rallied 7.81 percent to $2.90 in after-hours trading.

TRACON Pharmaceuticals Inc TCON reported a wider loss of 33 cents per share for Q2, while analysts estimated a loss of 31 cents per share. The stock rallied 19.59 percent to $2.90 in after-hours trading.

On The Radar

Earnings

Before the Market Open

• Aldeyra Therapeutics Inc ALDX Q2 EPS $(0.46) Misses $(0.43) Estimate
• Loxo Oncology Inc LOXO Q2 Adj. EPS $(1.68) Misses $(0.54) Estimate, Sales $42.601M Beat $28.91M Estimate
• Amneal Pharmaceuticals Inc AMRX Q2 EPS $0.24 Beats $0.22 Estimate, Sales $413.787M Miss $460.81M Estimate
• Catabasis Pharmaceuticals Inc CATB Q2 EPS $(0.20) Beats $(0.23) Estimate
• Jounce Therapeutics Inc JNCE Q2 EPS $(0.14) Beats $(0.37) Estimate, Sales $19.378M Beat $12.91M Estimate
• Pieris Pharmaceuticals Inc PIRS Q2 Sales $11.691M Miss $12.71M Estimate, EPS $0.00 vs $(0.01) Est.
• BioLife Solutions Inc BLFS Q2 EPS $0.05 Beats $0.04 Estimate, Sales $5.178M Beat $5.15M Estimate
• Fibrocell Science Inc FCSC Q2 EPS $(1.03) Misses $(0.42) Estimate
• Portola Pharmaceuticals Inc PTLA Q2 EPS $(1.61) Misses $(1.49) Estimate, Sales $4.011M Miss $6.35M Estimate

After the Market Close

• BioDelivery Sciences International, Inc. BDSI
• Puma Biotechnology Inc PBYI
• Kindred Biosciences Inc KIN
• CareDx Inc CDNA
• Interpace Diagnostics Group Inc IDXG
• Dova Pharmaceuticals Inc DOVA
• Endologix, Inc. ELGX
• Pernix Therapeutics Holdings Inc PTX
• Organovo Holdings Inc ONVO
• ICU Medical, Incorporated ICUI
• Caladrius Biosciences Inc CLBS
• CymaBay Therapeutics Inc CBAY
• Zosano Pharma Corp ZSAN
• KemPharm Inc KMPH
• Taro Pharmaceutical Industries Ltd. TARO
• Viking Therapeutics Inc VKTX